Abstract
Using a blood cell separator, lymphocytes were collected from otherwise healthy convalescents suffering from herpetic infections. A specific anti-herpes dialysate (AH-DLE) was prepared from the lymphocytes, using standard procedures. Patients with recurrent herpetic infections were treated with a single dose of the dialysate, at the initial signs of herpetic infection (group A), with two doses (group B) or with three doses (group C). A total number of 37 patients (29 women, 8 men, age range 15–73 years) were treated. No improvement was observed in 7 patients (18.9%), whilst 7 patients did not manifest any exacerbation of their herpetic infection in the course of the one-year follow-up. The remaining 62.2% of the patients showed a marked improvement: decrease of the frequency and/or duration or relapses. Before AH-DLE administration, the mean number of herpes relapses in this group of patients was 12 p.a.. After therapy, the number of relapses decreased to 3.5 p.a.. No statistically significant difference was observed between groups A and B. The least favourable results were registered in group C. However, this group included 6 female patients extremely resistant to the previously therapeutic attempts, including inosiplex, non-specific DLE or acyclovir. Thus, even in this group, the therapy was successful in 50% of the patients.
Similar content being viewed by others
Abbreviations
- AH:
-
anti-herpes
- DLE:
-
dialysable leucocyte extract
- TF:
-
transfer factor
References
Kirkpatrick CH: Transfer factor. J Allerg Cl 1988; 81: 803.
Fudenberg HH & Fudenberg HL. Transfer factor: Past, present and future. Ann R Pharm 1989; 29: 475–516.
Pekarek J & Cech K. Transfer Factor SEVAC — perspectives of its medical application (in Czech), Zpravy SEVAC 1986; 1: 3–36.
Pekarek J, Cech K & Rovensky J. Leukocyte dialyzates -Transfer factor (in Czech). Klin Imunol a Alegologia 1991; 1: 9–15.
Jansak J: Transfer Factor in clinical immunology (in Czech). Klin Imunol a Alergol 1994; 4: 84–87.
Steele RW, Heberling RL & Eichberg JW. Prevention of herpes simplex virus type 1 fatal dissemination in patients with human transfer factor. In: Ascher MS, Gottlieb AA, Kirkpatrick CH, eds. Transfer factor; basic properties and clinical applications. New York: Academic Press, 1976: 381–86.
Khan A, Ilansen B & Hill NO. Transfer factor in the treatment of herpes simplex types 1 and 2. Dermatologica 1981; 163: 177–85.
Dwyer JM: The use of antigen specific transfer factor in the management of infections with herpes viruses. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of Transfer Factor. New York: Academic Press, 1983: 233–43.
Viza D, Rosenfeld F, Phillips J, Vich JM, Denis J, Bonissent JF & Dobge K. Specific bovine transfer factor for the treatment of herpes infections. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of Transfer Factor. New York: Academic Press, 1983: 233–43.
Viza D, Vich JM, Philips J & Rosenfield F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphokine Res 1985; 4: 27–30.
Bystron J, Bohac S & Hraunova J. Combined immunostimulation with transfer factor and bacterial lysate in the treatment of recurrent herpetic infections (in Czech). Prakt Lekar 1993; 73: 159–61.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Byston, J., Cech, K., Pekarek, J. et al. Effect of anti-herpes specific transfer factor. Biotherapy 9, 73–75 (1996). https://doi.org/10.1007/BF02628660
Issue Date:
DOI: https://doi.org/10.1007/BF02628660